Adstiladrin
(Adebrelimab)Phase 3Monoclonal antibody
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Adebrelimab is used to treat certain types of cancer, specifically a blood cancer called diffuse large B-cell lymphoma (DLBCL), by helping the immune system recognize and attack cancer cells.[1] Adstiladrin is currently being investigated across 34 indications[3], with its most advanced program in Phase 3.[1]
Adstiladrin is one of 689 small molecule programs targeting Small Cell Carcinoma. It is currently in Phase 3.
34
Indications
108
Total Trials
104
Active Trials
688
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 34 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Adstiladrin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3
Megace
Bristol-Myers SquibbPreclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
MS Contin
Merck & Co.Preclinical
Lexiscan
AstellasPreclinical
Adenocard
AstellasPreclinical
Recentin
NNational Cancer Institute (NCI)
Preclinical
Spravato
WWim Janssens
Preclinical
Avastin
RochePreclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Q3 2026
Phase 2Recruiting
Oral Squamous Cell Carcinoma
NCT06277791
Phase 2Not yet recruiting
Hepatocellular Carcinoma
NCT05975463
Phase 2Not yet recruiting
Chemoradiotherapy
NCT06464614
Phase 1/2Active, not recruiting
Patients With Advanced Solid Tumors
NCT06385678
Phase 2Recruiting
Head and Neck Squamous Cell Carcinoma
NCT07055841
N/ARecruiting
Small Cell Lung Cancer
NCT06480864
Clinical
Trials by Indication[1]
Breast Cancer9 trials
Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis
Recruiting·—·Phase 2·NCT06418594·30 enrolled
Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
Not yet recruiting·—·Phase 2·NCT06433609·131 enrolled
Show 6 more trials
PD-L1 Inhibitor + RT ± Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast Cancer
Not yet recruiting·—·Phase 2·NCT06842472·70 enrolled
Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer
Not yet recruiting·—·Phase 2·NCT07317778·249 enrolled
To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06470633·29 enrolled
Small Cell Lung Cancer7 trials
Show 4 more trials
Hepatocellular Carcinoma6 trials
Pancreatic Cancer6 trials
Show 3 more trials
Patients With Advanced Solid Tumors6 trials
46 more indications
Non-Small Cell Lung Cancer4 trials
A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer
Not yet recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 2·NCT07031154·43 enrolled
Neoadjuvant Therapy4 trials
Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC
Not yet recruiting·—·Phase 2·NCT07035392·32 enrolled
Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06684158·70 enrolled
Biliary Tract Cancer4 trials
Gastric Cancer3 trials
RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06385873·32 enrolled
Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
Not yet recruiting·—·Phase 2·NCT06881017·140 enrolled
Metastatic Colorectal Cancer3 trials
Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer
Recruiting·TThe Fourth Affiliated Hospital of Zhejiang University School of Medicine·Phase 2·NCT06282445·36 enrolled
Advanced Solid Tumors3 trials
Gastroesophageal Junction Adenocarcinoma2 trials
Colorectal Cancer2 trials
Esophageal Squamous Cell Carcinoma2 trials
Chemoradiotherapy2 trials
Nasopharyngeal Carcinoma2 trials
Esophageal Cancer2 trials
Chemotherapy2 trials
Intrahepatic Cholangiocarcinoma2 trials
Concurrent Chemoradiotherapy2 trials
First-line Treatment2 trials
Ovarian Cancer2 trials
Urothelial Carcinoma2 trials
Biliary Tract Neoplasms2 trials
Oral Squamous Cell Carcinoma1 trial
Rectal Adenocarcinoma1 trial
Oligometastatic1 trial
Lung Cancer1 trial
Malignancies1 trial
Surufatinib1 trial
A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06375642·30 enrolled
Cervical Cancer1 trial
Microwave Ablation1 trial
A Study of Microwave Ablation Combined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Solid Tumors
Not yet recruiting·—·Phase 2·NCT06537505·60 enrolled
Pancreatic1 trial
Bladder Carcinoma1 trial
Triple-Negative Breast Cancer1 trial
Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer
Not yet recruiting·—·Phase 2·NCT06229067·182 enrolled
Head and Neck Squamous Cell Carcinoma1 trial
Soft Tissue Sarcoma1 trial
Capecitabine1 trial
A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer
Recruiting·—·Phase 1/2·NCT06776770·52 enrolled
Neoadjuvant Treatment1 trial
Adebrelimab Neoadjuvant Treatment for Resectable ESCC
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·N/A·NCT07388095·22 enrolled
Efficacy and Safety1 trial
Solid Tumors1 trial
Unresectable Biliary Tract Carcinoma1 trial
Conversion Therapy1 trial
Adebrelimab, Apatinib & SOX for Conversion Therapy in Advanced Gastric/GEJ Cancer
Recruiting·—·Phase 2·NCT07353684·49 enrolled
Small Cell Carcinoma1 trial
A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma
Not yet recruiting·—·Phase 2·NCT06478264·40 enrolled
Prostate Cancer1 trial
Hypofractionated Radiotherapy1 trial
Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06914050·30 enrolled
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Adebrelimab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details